News Sentiment

TNDM sentiment intelligence

Tandem Diabetes Care Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 56 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Medical Devices Read-through group
Latest close 15.41 Week of 10 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Earnings

75/100 classification confidence.

Company focus 44

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

+0.6% over one week, -7.2% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

Analysts Offer Insights on Healthcare Companies: Tandem Diabetes Care (TNDM) and Boston Scientific (BSX)

Market Reaction

Balanced read

51/100 confidence

News tone and price action are not far from neutral.

Primary event Earnings 75/100 classification
One-week reaction 0.6% Price digesting
Trend fit Trend inactive -7.2% over four weeks
Fair value -40.7% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 11
Neutral 40
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 44
Industry context 12
Sector context 0

Sources

Coverage mix

Publishers
Market source 21
StockStory 5
TradingView 4
Simply Wall Street 3
Business Wire 3
Quartr 2
Moomoo 2
Insider Monkey 2

Event Lens

What the news is about

Classified themes
Earnings 26
Market update 19
Analyst action 5
Guidance 3
Regulatory and legal 1
Macro sensitivity 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 56
The Globe and Mail Direct company coverage

Analysts Offer Insights on Healthcare Companies: Tandem Diabetes Care (TNDM) and Boston Scientific (BSX)

RBC Capital maintained a Buy rating on Tandem Diabetes Care (TNDM) with a price target of $30.00. TD Cowen maintained a Buy rating on Boston Scientific (BSX) with a price target of $61.00, while the general analyst consensus for Boston Scientific is a Strong Buy with a $71.20 ave

Tone
Positive 73/100
Event
Analyst action
Published
15 Jul 2026 06:13
Source
The Globe and Mail
Simply Wall Street Direct company coverage

Tandem Diabetes Care (TNDM) Expands Abbott Compatibility As Undervalued Narrative Faces A Fresh Test

Tandem Diabetes Care (TNDM) has announced that its t:slim X2 insulin pump now integrates with Abbott’s FreeStyle Libre 3 Plus CGM in five European countries. Despite this product expansion, the company's share price has experienced recent weakness, leading to a discussion about w

Tone
Positive 63/100
Event
Market update
Published
13 Jul 2026 09:09
Source
Simply Wall Street
Stock Traders Daily Direct company coverage

Understanding the Setup: (TNDM) and Scalable Risk

This article analyzes Tandem Diabetes Care Inc. (NASDAQ: TNDM), identifying weak near and mid-term sentiment despite a positive long-term outlook. It highlights a significant 120.5:1 risk-reward setup targeting a 31.4% gain against 0.3% risk, and provides three distinct trading s

Tone
Positive 64/100
Event
Guidance
Published
10 Jul 2026 08:58
Source
Stock Traders Daily
timothysykes.com Direct company coverage

Tandem Diabetes Care Inc., (TNDM) Stock Price | Live Quotes & Charts | NASDAQ

This page provides live stock quotes and charts for Tandem Diabetes Care Inc. (TNDM), showing its current price as $15.37 with a slight decrease of $0.05 (-0.33%). It also indicates that there are currently no analyst ratings or earnings information available for the company. The

Tone
Neutral 50/100
Event
Earnings
Published
09 Jul 2026 22:40
Source
timothysykes.com
Quartr Direct company coverage

Tandem Diabetes Care (TNDM) Goldman Sachs 46th Annual Global Healthcare Conference summary

Tandem Diabetes Care (TNDM) presented a summary of its performance, product pipeline, and market strategy at the Goldman Sachs 46th Annual Global Healthcare Conference. The company reports strong growth driven by Mobi and anticipates further expansion with Type II approval and ne

Tone
Positive 81/100
Event
Regulatory and legal
Published
09 Jul 2026 20:40
Source
Quartr
Simply Wall Street Direct company coverage

Tandem’s Expanded Libre 3 Plus Integration Could Be A Game Changer For Tandem Diabetes Care (TNDM)

Tandem Diabetes Care has expanded its t:slim X2 insulin pump's compatibility with Abbott's FreeStyle Libre 3 Plus continuous glucose sensor in five European countries, offering 15-day wear and minute-by-minute data. This integration, alongside recent CE mark approvals for Control

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 15:48
Source
Simply Wall Street
Quartr Direct company coverage

Tandem Diabetes Care (TNDM) Stifel 2024 Healthcare Conference Summary

Tandem Diabetes Care presented a summary of their Stifel 2024 Healthcare Conference, highlighting strong business performance with over 20% year-over-year pump shipment growth and high renewal rates. The company expects continued growth in 2025 and beyond, driven by new product l

Tone
Positive 81/100
Event
Guidance
Published
08 Jul 2026 23:09
Source
Quartr
Moomoo Direct company coverage

Citi Maintains Tandem Diabetes Care(TNDM.US) With Hold Rating, Maintains Target Price $17

Citi analyst Joanne Wuensch has maintained a "Hold" rating for Tandem Diabetes Care (TNDM.US) and kept the target price at $17. According to TipRanks data, Wuensch has a 51.6% success rate and a 1.1% average return over the past year. This information is provided for informationa

Tone
Neutral 50/100
Event
Analyst action
Published
08 Jul 2026 21:48
Source
Moomoo
TradingView Direct company coverage

Does TNDM Stock Still Deserve a Place in Your Portfolio?

Tandem Diabetes Care (TNDM) is positioned for growth due to the increasing prevalence of diabetes and rising demand for automated insulin delivery systems, along with a new pay-as-you-go reimbursement model that may strengthen its financial position. However, the company faces po

Tone
Positive 68/100
Event
Macro sensitivity
Published
07 Jul 2026 14:12
Source
TradingView
Insider Monkey Direct company coverage

Is the Market Underestimating Tandem Diabetes Care, Inc. (TNDM)’s Transition Risks?

Tandem Diabetes Care, Inc. (TNDM) is facing a significant "transformational shift" in its economic model due to a transition to PayGo pharmacy, raising execution risks according to Deutsche Bank. Despite a Hold rating and a $15.50 price target from Deutsche Bank, TNDM recently re

Tone
Neutral 50/100
Event
Analyst action
Published
07 Jul 2026 01:53
Source
Insider Monkey
Insider Monkey Direct company coverage

10 Best Get Rich Quick Stocks to Buy Right Now

This article identifies Tandem Diabetes Care, Inc. (NASDAQ: TNDM) as one of the best get-rich-quick stocks, citing its 86.03% upside potential and recent CE mark for expanded indications of its automated insulin delivery systems in Europe. Despite a "Hold" rating from Deutsche Ba

Tone
Neutral 50/100
Event
Analyst action
Published
06 Jul 2026 18:10
Source
Insider Monkey
Medical Product Outsourcing Direct company coverage

Tandem Diabetes Care Launches t:slim X2 Insulin Pump Compatibility With Abbott's FreeStyle Libre 3 Plus CGM Sensor

Tandem Diabetes Care has made its t:slim X2 insulin pump, featuring Control-IQ+ technology, compatible with Abbott's FreeStyle Libre 3 Plus continuous glucose monitoring (CGM) sensor in several European countries, including the UK, Switzerland, Sweden, Finland, and Italy. This in

Tone
Positive 70/100
Event
Market update
Published
06 Jul 2026 14:43
Source
Medical Product Outsourcing
Investing.com Direct company coverage

Tandem Diabetes faces earnings test as pay-as-you-go shift weighs

Tandem Diabetes Care Inc., an insulin-pump maker, is set to report its first-quarter earnings, with analysts anticipating a loss of 44 cents per share on $242.1 million in revenue. This projected decline is largely due to the company's transition to a pay-as-you-go pharmacy model

Tone
Neutral 50/100
Event
Earnings
Published
05 Jul 2026 21:12
Source
Investing.com
TradingView Direct company coverage

ETFs Investing in Tandem Diabetes Care, Inc. Stocks

This article lists various Exchange Traded Funds (ETFs) that hold stocks of Tandem Diabetes Care, Inc. The ETFs are sorted by their market value and include details such as issuer, management style, focus, expense ratio, assets under management (AUM), price, and 3-year NAV total

Tone
Neutral 50/100
Event
Market update
Published
04 Jul 2026 07:09
Source
TradingView
Finviz Direct company coverage

TNDM - Tandem Diabetes Care Inc Options

This article provides a detailed financial overview of Tandem Diabetes Care Inc. (TNDM), including its last closing price, market capitalization, key financial ratios, earnings per share, sales performance, and insider/institutional ownership. It also presents various performance

Tone
Negative 39/100
Event
Earnings
Published
03 Jul 2026 14:40
Source
Finviz
MSN Direct company coverage

Insulin pump makers Tandem and Insulet post contrasting Q2 results

Tandem Diabetes Care and Insulet, two major insulin pump manufacturers, have reported contrasting financial results for the second quarter. While Tandem saw a decline in its pump shipments and revised its full-year guidance downwards, Insulet exceeded revenue expectations and rai

Tone
Neutral 50/100
Event
Earnings
Published
02 Jul 2026 18:10
Source
MSN
Moomoo Direct company coverage

Tandem Diabetes Care to Announce Second Quarter 2026 Financial Results on August 6, 2026

Tandem Diabetes Care (NASDAQ: TNDM) will report its second-quarter 2026 financial results on August 6, 2026, after the market closes. The company will also host a conference call and live webcast to discuss the results, providing an opportunity for investors and interested partie

Tone
Neutral 50/100
Event
Earnings
Published
02 Jul 2026 08:40
Source
Moomoo
Simply Wall Street Direct company coverage

What Tandem Diabetes Care (TNDM)'s CGM Expansion and New Tubeless Rival Mean For Shareholders

Tandem Diabetes Care recently expanded its t:slim X2 insulin pump's compatibility with Abbott's FreeStyle Libre 3 Plus CGM in Europe, while facing new competition from Modular Medical's Pivot tubeless insulin patch pump. This dual development highlights both the growth of Tandem'

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 08:10
Source
Simply Wall Street
Business Wire Direct company coverage

Tandem Diabetes Care Launches t:slim X2 Insulin Pump Compatibility with Abbott FreeStyle Libre 3 Plus Sensor in Five International Markets

Tandem Diabetes Care announced the launch of t:slim X2 insulin pump compatibility with Abbott’s FreeStyle Libre 3 Plus continuous glucose monitoring (CGM) sensor in the United Kingdom, Switzerland, Sweden, Finland, and Italy. This integration expands CGM choices for users of the

Tone
Positive 74/100
Event
Market update
Published
01 Jul 2026 12:40
Source
Business Wire
Finviz Direct company coverage

TNDM - Tandem Diabetes Care Inc Latest SEC Filings

This article provides comprehensive financial data and performance metrics for Tandem Diabetes Care Inc. (TNDM). It highlights key figures such as the last closing price, market capitalization, income, sales, various financial ratios, and stock performance over different periods.

Tone
Negative 33/100
Event
Market update
Published
01 Jul 2026 06:39
Source
Finviz
Market source Direct company coverage

Why Tandem Diabetes (TNDM) Shares Are Sliding Today

Shares of Tandem Diabetes Care (NASDAQ:TNDM) fell 2.5% after Modular Medical, a company founded by Tandem's original founder, introduced a new competing tubeless insulin patch pump. This news has raised concerns among investors about increased competition and potential market sha

Tone
Negative 39/100
Event
Market update
Published
01 Jul 2026 00:39
Source
Market source
富途牛牛 Direct company coverage

Press Release: Tandem Diabetes Care to Announce Second Quarter 2026 Financial Results on August 6, 2026

Tandem Diabetes Care (NASDAQ: TNDM) will release its second quarter 2026 financial results on August 6, 2026, after the market closes. The company will also host a conference call and live webcast to discuss these results at 4:30 p.m. ET (1:30 p.m. PT) on the same day. Investors

Tone
Neutral 50/100
Event
Earnings
Published
30 Jun 2026 20:09
Source
富途牛牛
TradingView Direct company coverage

Tandem Diabetes Care, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.066666 Sh

This page provides access to financial disclosures and regulatory filings for Tandem Diabetes Care, Inc., specifically for its unsponsored Brazilian Depositary Receipts (T2ND34). It lists various documents from 2025 and 2026, including earnings reports, conference transcripts, an

Tone
Positive 82/100
Event
Earnings
Published
30 Jun 2026 17:12
Source
TradingView